Filing Flows › BioXcel Therapeutics (BTAIQ) › R&D spending
BioXcel Therapeutics (BTAIQ) R&D spending by quarter
BioXcel Therapeutics' R&D spending was $3.2M in Q2 2026 (second quarter 2026), +7% from Q1 2026. Over the last 7 quarters it ranged from $3.0M (Q1 2026) to $10.3M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $3.2M | +7% | -69% |
| Q1 2026 | $3.0M | -56% | -35% |
| Q4 2025 | $6.7M | -23% | +14% |
| Q3 2025 | $8.7M | -15% | — |
| Q2 2025 | $10.3M | +125% | — |
| Q1 2025 | $4.6M | -23% | — |
| Q4 2024 | $5.9M | — | — |
Q2 2026 at a glance
BioXcel Therapeutics, Q2 2026: revenue $182K (+52% year over year), net loss $14.7M, operating cash flow −$6.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is BioXcel Therapeutics' R&D spending?
BioXcel Therapeutics' R&D spending was $3.2M in Q2 2026 (second quarter 2026), +7% from Q1 2026.
How has BioXcel Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $3.0M (Q1 2026) to $10.3M (Q2 2025).